PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCarisoprodol
Carisoprodol
Carisoprodol, Soma (carisoprodol) is a small molecule pharmaceutical. Carisoprodol was first approved as Soma on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, muscle spasticity, myositis, and pain amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Carisoprodol, Soma (discontinued: Carisoprodol, Rela, Soma)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carisoprodol
Tradename
Company
Number
Date
Products
SOMAMylanN-011792 RX1982-01-01
2 products, RLD
Show 2 discontinued
Aspirin
+
Carisoprodol
Tradename
Company
Number
Date
Products
SOMA COMPOUNDMeda ABN-012365 DISCN1983-07-11
1 products
Hide discontinued
Aspirin
+
Carisoprodol
+
Codeine phosphate
Tradename
Company
Number
Date
Products
SOMA COMPOUND W/ CODEINEMeda ABN-012366 DISCN1983-07-11
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aquabain antibacterial fresh and relaxC2002632024-12-02
carisoprodolANDA2025-02-05
carisoprodol and aspirinANDA2010-12-10
carisoprodol tablets, usp, 350 mgANDA2025-02-03
cbd clinic relax massageC2002632025-01-28
chakra aroma relaxing colorOTC monograph not final2019-02-19
coupling chamomile relax premium massagelotionunapproved drug other2022-01-13
coupling lavender relax premium massagelotionunapproved drug other2022-01-13
curestem cell healer c10 programunapproved drug other2020-06-08
curestem cell healer c5 programunapproved drug other2020-06-05
Show 55 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
M03: Muscle relaxants
M03B: Muscle relaxants, centrally acting agents
M03BA: Carbamic acid esters, centrally acting muscle relaxants
M03BA02: Carisoprodol
M03BA52: Carisoprodol, combinations excl. psycholeptics
M03BA72: Carisoprodol, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Low back painD017116M54.522
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCarisoprodol
INNcarisoprodol
Description
Carisoprodol is a carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. It has a role as a muscle relaxant.
Classification
Small molecule
Drug classCarbamate
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
Identifiers
PDB
CAS-ID78-44-4
RxCUI
ChEMBL IDCHEMBL1233
ChEBI ID3419
PubChem CID2576
DrugBankDB00395
UNII ID21925K482H (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Carisoprodol
+
Aspirin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Carisoprodol
+
Aspirin
+
Codeine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Carisoprodol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 27,557 documents
View more details
Safety
Black-box Warning
Black-box warning for: Relafen ds
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
90,760 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use